Abbott Laboratories (NYSE:ABT) has had a rough go of it over the past few years. Sales growth hasn't met market expectations, and the company has faced various legal and regulatory challenges. But is the healthcare leader ready to turn over a new leaf? Abbott Laboratories announced its third-quarter update on Oct. 21, and along with its financial results, the company shared news that investors should welcome with open arms. Image source: The Motley Fool. Abbott Laboratories' third-quarter financial results were pretty good. The company's sales were $13 billion, growing 7% year over year on a comparable basis. The healthcare leader's adjusted earnings per share came in at $1.42, 9% higher than the year-ago period. Abbott's medical device and established pharmaceuticals segments remain the biggest growth drivers.
CryptoAlerta — análise de criptomoedas e mercado em tempo real